Hims & Hers

Hims & Hers CEO Andrew Dudum stated that companies with large internal datasets can achieve significant AI cost reductions, potentially saving up to 80% by transitioning from big AI models to open-weight models. He noted that training models on a company's specific use cases leads to superior performance. This focus is part of a broader industry trend toward optimizing AI spending, including implementing model routing.

Hims & Hers reported that its revenue grew 38% to $753 million, while raising its full-year revenue outlook to $3.1–$3.3 billion. Despite the strong growth metrics, the telehealth company posted a net loss of $86.3 million during the second quarter.

The article highlights recent cybersecurity threats and updates, including fake Fortnite rewards stealing accounts, the AtlasRAT malware via fake Flash Player installs, and Hims & Hers facing lawsuits over data privacy failures. It also covers Apple's AI worm issue, a $1.8 million crypto app scam, and vulnerabilities in the Vatican's Click To Pray app exposing 700,000 users' data. Malwarebytes announces new security tools and updates.

The FTC, along with Utah and California, has sued Hims & Hers, a telehealth provider, for allegedly sharing sensitive health data with third-party ad platforms like Meta and Snap, deceptive billing practices that charged users before consultations, and making subscription cancellations difficult. The lawsuit highlights privacy violations and dark patterns in user experience design.

Hims & Hers, a digital telehealth platform, is facing a civil lawsuit for allegedly sharing users' health information with online advertisers despite privacy assurances. The lawsuit accuses the company of violating user privacy by transmitting health data to social media platforms.

Hims & Hers, a digital telehealth platform, is facing a civil lawsuit over accusations of sharing users' health information with social media advertisers despite privacy assurances. The lawsuit claims the company violated user privacy by transmitting health data to online advertisers.

An FDA advisory panel rejected a Duchenne muscular dystrophy drug by a 9-to-3 vote due to insufficient effectiveness data, and the FTC sued Hims & Hers over alleged misleading health data practices and subscription billing issues.

The FTC is suing Hims & Hers for allegedly sharing customers' sensitive health data with Meta, Snap, and other advertising platforms, and for misleading them about billing and subscription cancellation processes. The company is accused of violating privacy assurances and enrolling customers in recurring subscriptions without proper consent.

The Federal Trade Commission (FTC) sued Hims & Hers, alleging the telehealth company shared users' health data with Meta, Snap, and other third parties, while also deceiving customers about billing and cancellation practices. Hims & Hers responded, claiming the FTC ignored evidence and industry standards.

Hims & Hers stock declined following a Federal Trade Commission (FTC) lawsuit alleging the telehealth company shared sensitive health data with Meta and Snap while misleading users about billing and cancellation policies.

Hims & Hers shares fell 10% following a lawsuit by the FTC over alleged health data sharing with Meta and Snap, billing practices, and subscription cancellation issues.

Novo Nordisk sued Eli Lilly for misleading advertising in the US weight-loss drug market, alleging outdated weight-loss comparisons. Novo also previously sued Hims & Hers over a copycat version of Wegovy. The dispute highlights differences in global advertising regulations, as most countries prohibit ads for prescription-only medications.

The FDA is considering approval for compounding pharmacies to legally mix wellness peptides like BPC-157 and TB-500, which could create a $30 billion market. Telehealth companies like Hims & Hers, which previously profited from compounded Ozempic alternatives, are positioning to expand into peptide therapies despite limited long-term safety data.

Telehealth companies like Hims & Hers and Teladoc have grown into a multi-billion-dollar industry, but face legal challenges in over 30 states where corporations are prohibited from practicing medicine. To comply, these companies partner with independent medical groups owned by physicians who hold multiple state licenses, ensuring clinical decisions prioritize patient needs over corporate profits.

Hims & Hers' stock plummets 15% after reporting a first-quarter loss and weak earnings guidance. The company had previously reached a deal with Novo Nordisk to sell the GLP-1 weight loss drug Wegovy on its platform. This partnership was announced in March.

RFK Jr. advocates for loosening federal restrictions on peptides, potentially boosting telehealth companies, compounding pharmacies, and longevity clinics. The FDA will review peptide regulations in July, while experts debate their efficacy and safety, with market projections reaching $180 billion in five years.